BIOMARKERS FOR CLINICAL CANCER MANAGEMENT

A method is provided for determining breast cancer, a predisposition to breast cancer, or the prognosis of a breast cancer in a subject, said method comprising in a sample from said subject determining the methylation status of at least one gene locus including regulatory sequences of said gene locu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	OVERGAARD, JENS, WOJDACZ, TOMASZ KAZIMIERZ, HANSEN, LISE LOTTE
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES DIAGNOSIS ELECTROTHERAPY ENZYMOLOGY HUMAN NECESSITIES HYGIENE IDENTIFICATION MAGNETOTHERAPY MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PROCESSES OF PREPARING SUCH COMPOSITIONS RADIATION THERAPY SPIRITS SURGERY ULTRASOUND THERAPY VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A method is provided for determining breast cancer, a predisposition to breast cancer, or the prognosis of a breast cancer in a subject, said method comprising in a sample from said subject determining the methylation status of at least one gene locus including regulatory sequences of said gene locus, wherein said genelocusis selected from the group consisting of PHOX2B, FLJ3247, GHSR, HOXB13, HTR1B, ONECUT, POU4F, WT1, LHX1, BC008699, BX161496, CA10, NR2E1, SIX6, SLC38A4, TITF, TMTM132D, CRH, NKX2-3 and HMX. L'invention concerne un procédé pour la détermination du cancer du sein, d'une prédisposition au cancer du sein, ou du pronostic d'un cancer du sein chez un sujet, ledit procédé comprenant un échantillon provenant dudit sujet, déterminant le statut de méthylation d'au moins un locus génique comprenant des séquences régulatrices dudit locus génique, ledit locus génique étant choisi dans le groupe consistant en PHOX2B, FLJ3247, GHSR, HOXB13, HTR1B, ONECUT, POU4F, WT1, LHX1, BC008699, BX161496, CA10, NR2E1, SIX6, SLC38A4, TITF, TMTM132D, CRH, NKX2-3 et HMX.